Back to Search Start Over

Antibody Responses to NY-ESO-1 in Primary Breast Cancer Identify a Subtype Target for Immunotherapy.

Authors :
Hamaï, Ahmed
Duperrier-Amouriaux, Karine
Pignon, Pascale
Raimbaud, Isabelle
Memeo, Lorenzo
Colarossi, Cristina
Canzonieri, Vincenzo
Perin, Tiziana
Classe, Jean-Marc
Campone, Mario
Jézéquel, Pascal
Campion, Loïc
Ayyoub, Maha
Valmori, Danila
Source :
PLoS ONE; 2011, Vol. 6 Issue 6, p1-7, 7p
Publication Year :
2011

Abstract

The highly immunogenic human tumor antigen NY-ESO-1 (ESO) is a target of choice for anti-cancer immune therapy. In this study, we assessed spontaneous antibody (Ab) responses to ESO in a large cohort of patients with primary breast cancer (BC) and addressed the correlation between the presence of anti-ESO Ab, the expression of ESO in the tumors and their characteristics. We found detectable Ab responses to ESO in 1% of the patients. Tumors from patients with circulating Ab to ESO exhibited common characteristics, being mainly hormone receptor (HR)<superscript>-</superscript> invasive ductal carcinomas of high grade, including both HER2<superscript>-</superscript> and HER2<superscript>+</superscript> tumors. In line with these results, we detected ESO expression in 20% of primary HR<superscript>-</superscript> BC, including both ESO Ab<superscript>+</superscript> and Ab<superscript>-</superscript> patients, but not in HR<superscript>+</superscript> BC. Interestingly, whereas expression levels in ESO<superscript>+</superscript> BC were not significantly different between ESO Ab<superscript>+</superscript> and Ab<superscript>-</superscript> patients, the former had, in average, significantly higher numbers of tumor-infiltrated lymph nodes, indicating that lymph node invasion may be required for the development of spontaneous anti-tumor immune responses. Thus, the presence of ESO Ab identifies a tumor subtype of HR<superscript>-</superscript> (HER2<superscript>-</superscript> or HER2<superscript>+</superscript>) primary BC with frequent ESO expression and, together with the assessment of antigen expression in the tumor, may be instrumental for the selection of patients for whom ESO-based immunotherapy may complement standard therapy. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
19326203
Volume :
6
Issue :
6
Database :
Complementary Index
Journal :
PLoS ONE
Publication Type :
Academic Journal
Accession number :
74275138
Full Text :
https://doi.org/10.1371/journal.pone.0021129